报价延迟最少15分钟:2026/04/25 19:10 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.68 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.04/0.47
|
|
企业价值
1.28B
|
| 资产负债 |
|
每股账面净值
3.92
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
376.13M
|
|
每股收益
3.10
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue. |
